Balchem reported third-quarter net sales of 290,658 and net earnings of 46,728, and nine-month net sales of 845,364 and net earnings of 131,628, all in thousands.
BCPC · Balchem Corp
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Balcom Corporation reported record third-quarter consolidated revenue of $291 million, up 8.6%, and record adjusted EBITDA of $80 million, up 12.4%; net income was $47 million, up 16%, marking its 29th consecutive quarter of year-over-year adjusted EBITDA growth.
Balchem Corporation reported third-quarter net sales of $290.7 million, net earnings of $46.7 million, adjusted EBITDA of $80.3 million and free cash flow of $57.9 million for the quarter ended September 30, 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Jul 31, 2026TL;DR. Balchem posted record Q2 2026 results with double-digit net sales and earnings growth across all three segments and refinanced its revolving credit facility to a larger $650M capacity maturing 2031. Animal Nutrition & Health led with 15% sales growth driven by both volume and pricing, helped by European anti-dumping duties that are restoring share.
- + Record consolidated Q2 results with net sales up 11.2% to $284.0M and adjusted EBITDA up 12.6% to $77.9M.
- + All three segments delivered sales and earnings growth, with Human Nutrition & Health record sales up 10.0% to $176.9M and Specialty Products record sales up 8.9% to $40.5M.
- + Refinanced and expanded revolving credit facility to $650M with maturity extended to July 2031, providing more capacity to fund growth and acquisitions.
- + Returned $29M to shareholders via buybacks in Q2 ($114M over trailing twelve months) and paid down net debt to $88.8M with leverage ratio of 0.3x.
- − GAAP gross margin only expanded 10 bps to 36.5% as higher manufacturing input costs partially offset sales growth and efficiencies.
- − Q2 effective tax rate rose to 22.8% from 21.9% in the prior-year quarter, due to lower tax benefits from stock-based compensation.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted earnings from operations non-GAAP | 192.49M | Nine Months Ended September 30, 2026 | — |
| Adjusted EBITDA non-GAAP | 232.52M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Adjusted gross margin non-GAAP | 312.64M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Adjusted net earnings non-GAAP | 141.44M | Nine Months Ended September 30, 2026 | — |
| Adjusted net earnings per common share - diluted non-GAAP | $4.4 | Nine Months Ended September 30, 2026 | — |
|
|
|||
| EBITDA non-GAAP | 214.14M | Nine Months Ended September 30, 2026 | — |
| Free cash flow non-GAAP | 127.99M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Net debt non-GAAP | 57.7M | as of September 30, 2026 | — |
| Overall leverage ratio non-GAAP | 0.2 | as of September 30, 2026 | — |
| Adjusted earnings from operations, Human Nutrition and Health segment non-GAAP | 45.9M | the second quarter 2026 | — |
| Common stock repurchases | 29M | the second quarter 2026 | — |
| Common stock repurchases (trailing twelve months) | 114M | trailing twelve months ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Specialty Chemicals — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BCPC
this stock
Balchem Corp
|
$5.36B | +10.0% | +13.6% | 31.8 | 1.6% |
|
LIN
Linde PLC
|
$235.12B | +20.1% | +3.0% | 34.0 | 1.4% |
|
AIQUF
L Air Liquide SA
|
$132.78B | +10.8% | — | — | 0.0% |
|
ECL
Ecolab Inc.
|
$84.33B | +14.5% | +2.2% | 40.9 | 1.5% |
|
SHW
Sherwin Williams Co
|
$83.73B | +7.0% | +2.1% | 31.9 | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BCPC | -2.6% | -1.2% | +7.7% | -0.7% | +10.0% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | +1.3% | +4.4% | +11.1% | +2.6% | +2.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.